Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Immutep

Immunology

Immunology Today—January 8, 2026

This Immunology update captures a broad range of developments, including…

Endocrinology

Endocrinology Today—January 5, 2026

Catch up on the latest endocrinology highlights—from major developments and new…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Oncology Video Recap—March 2, 2026
Oncology Today—March 2, 2026
Hematology Today—March 2, 2026
AI in Healthcare and Digital Health Today—March 2, 2026
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”

Tags

AI-designed antibodies Alzheimer’s psychosis Atropos Health Biohaven CAD cancer care cancer vaccines cardiovascular-kidney-metabolic syndrome Celea Therapeutics Chronic myeloid leukemia circMTRNR2 Cluster headache competitive advantage Daewoong erythropoietin ESMO Immuno-Oncology Congress 2025 evinova Gastroenterology exit strategy GLP-1 innovation hair loss treatments health payments HeartFlow HSA international atherosclerosis society Karolinska Institutet manufacturing scale Meniere’s disease MetabERN Neoantigen vaccine Neuron replacement therapy NIHR Southampton NMPA China Oncology strategy Pain PBS Australia pharmacogenomics RIPTAC platform screening Semaglutide 7.2 mg Tecvayli Transcatheter edge-to-edge repair (TEER) TRIUMPH-4 urological cancer urticaria Zeltopa

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Oncology Video Recap—March 2, 2026
Oncology Today—March 2, 2026
Hematology Today—March 2, 2026
AI in Healthcare and Digital Health Today—March 2, 2026
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”

TAGS

AI-designed antibodies Alzheimer’s psychosis Atropos Health Biohaven CAD cancer care cancer vaccines cardiovascular-kidney-metabolic syndrome Celea Therapeutics Chronic myeloid leukemia circMTRNR2 Cluster headache competitive advantage Daewoong erythropoietin ESMO Immuno-Oncology Congress 2025 evinova Gastroenterology exit strategy GLP-1 innovation hair loss treatments health payments HeartFlow HSA international atherosclerosis society Karolinska Institutet manufacturing scale Meniere’s disease MetabERN Neoantigen vaccine Neuron replacement therapy NIHR Southampton NMPA China Oncology strategy Pain PBS Australia pharmacogenomics RIPTAC platform screening Semaglutide 7.2 mg Tecvayli Transcatheter edge-to-edge repair (TEER) TRIUMPH-4 urological cancer urticaria Zeltopa

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy